Remibrutinib cut annualized relapse rates significantly versus teriflunomide in both REMODEL-1 and REMODEL-2, and those Phase 3 results in relapsing MS now headline Novartis’s 46-abstract showing at MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting. Forty-six abstracts is a substantial footprint for a single company at one meeting, but the strategic weight sits squarely on the late-breaking slot granted to the REMODEL readout.
What makes the remibrutinib data worth watching closely is the mechanism. Unlike broadly immunosuppressive approaches, remibrutinib binds covalently to cysteine 481 in the inactive conformation of BTK, a specificity that is designed to spare kinases with similar active-site chemistry. BTK sits upstream in signaling for B cells, mast cells, macrophages, and other immune populations implicated in MS pathology, so inhibiting it orally, without the infusion burden of anti-CD20 therapies, is the practical promise the REMODEL trials were built to test. Both trials used teriflunomide as the active comparator, a standard oral therapy, which sets a meaningful efficacy bar rather than a placebo comparison.
The program design itself carries information. Running two identical randomized, double-blind Phase 3 studies concurrently, REMODEL-1 (NCT05147220) and REMODEL-2 (NCT05156281), is a regulatory strategy that gives Novartis replicated evidence from independent cohorts. Regulators generally view replication across separate trials as stronger than a single large study, so meeting primary endpoints in both trials positions a submission on firmer ground than a single pivotal study would. The safety profile reported alongside the efficacy data will matter equally: BTK inhibitors as a class have faced questions about off-target cardiovascular and hepatic signals, and how remibrutinib’s selectivity profile holds in a large relapsing MS population is what will determine whether the mechanism’s theoretical advantage translates to practice.
With 45 additional abstracts spanning the broader MS portfolio, the MSToronto presentation is partly a pipeline display, but the regulatory consequence the neurology community will track is whether the REMODEL replication holds up to the scrutiny the late-breaking slot invites.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
